See more : Harvard Bioscience, Inc. (HBIO) Income Statement Analysis – Financial Results
Complete financial analysis of Interpace Biosciences, Inc. (IDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Interpace Biosciences, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Hongbaoli Group Corporation, Ltd. (002165.SZ) Income Statement Analysis – Financial Results
- Friedrich Vorwerk Group SE (VH2.F) Income Statement Analysis – Financial Results
- CMS Energy Corporation (0HR4.L) Income Statement Analysis – Financial Results
- Aroundtown SA (0RUH.L) Income Statement Analysis – Financial Results
- PBF Energy Inc. (0KE0.L) Income Statement Analysis – Financial Results
Interpace Biosciences, Inc. (IDXG)
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.21M | 31.84M | 41.31M | 32.40M | 24.08M | 21.90M | 15.90M | 13.09M | 9.43M | 119.94M | 150.84M | 126.90M | 157.29M | 144.65M | 84.87M | 112.53M | 117.13M | 239.24M | 319.42M | 364.44M | 317.45M | 284.01M | 696.58M | 416.88M | 174.90M | 101.10M | 54.70M |
| Cost of Revenue | 16.31M | 13.61M | 23.37M | 21.67M | 15.89M | 10.20M | 7.36M | 6.64M | 6.91M | 101.39M | 126.43M | 100.04M | 124.82M | 112.45M | 58.59M | 108.02M | 85.52M | 183.40M | 257.48M | 265.61M | 228.37M | 254.14M | 560.80M | 302.28M | 128.90M | 77.70M | 44.30M |
| Gross Profit | 23.90M | 18.23M | 17.95M | 10.73M | 8.19M | 11.70M | 8.54M | 6.44M | 2.52M | 18.54M | 24.41M | 26.86M | 32.47M | 32.20M | 26.28M | 4.51M | 31.62M | 55.84M | 61.94M | 98.83M | 89.08M | 29.87M | 135.78M | 114.60M | 46.00M | 23.40M | 10.40M |
| Gross Profit Ratio | 59.44% | 57.26% | 43.44% | 33.10% | 34.02% | 53.43% | 53.71% | 49.25% | 26.74% | 15.46% | 16.18% | 21.17% | 20.64% | 22.26% | 30.96% | 4.01% | 26.99% | 23.34% | 19.39% | 27.12% | 28.06% | 10.52% | 19.49% | 27.49% | 26.30% | 23.15% | 19.01% |
| Research & Development | 636.00K | 703.00K | 1.88M | 2.80M | 2.81M | 2.12M | 1.46M | 1.65M | 2.29M | 255.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.36M | 10.97M | 13.67M | 20.77M | 14.55M | 8.50M | 9.15M | 10.50M | 16.92M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 10.23M | 9.13M | 10.07M | 9.25M | 11.12M | 8.42M | 6.57M | 5.46M | 10.36M | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.60M | 20.10M | 23.74M | 30.02M | 25.66M | 16.92M | 15.72M | 15.97M | 27.28M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 39.37M | 44.83M | 50.69M | 88.82M | 63.64M | 67.25M | 76.83M | 123.08M | 71.65M | 29.10M | 13.90M | 7.90M |
| Other Expenses | 868.00K | 1.27M | 4.06M | 4.46M | 3.65M | 263.00K | -2.13M | 14.00K | -93.00K | -68.00K | -59.00K | -28.00K | 2.89M | 20.57M | 0.00 | 333.00K | 1.06M | -3.28M | 53.49M | 0.00 | 2.10M | 0.00 | 0.00 | 2.08M | 1.20M | 300.00K | 100.00K |
| Operating Expenses | 20.23M | 22.07M | 29.68M | 37.28M | 32.12M | 22.30M | 20.43M | 21.38M | 33.38M | 29.93M | 28.69M | 27.87M | 37.17M | 36.51M | 48.74M | 39.70M | 45.90M | 47.41M | 88.82M | 63.64M | 69.35M | 76.83M | 123.08M | 73.72M | 30.30M | 14.20M | 8.00M |
| Cost & Expenses | 37.41M | 35.68M | 53.05M | 58.95M | 48.01M | 32.49M | 27.79M | 28.02M | 40.29M | 131.32M | 155.12M | 127.91M | 161.99M | 148.96M | 107.33M | 147.72M | 131.41M | 230.80M | 346.30M | 329.25M | 297.72M | 330.97M | 683.88M | 376.00M | 159.20M | 91.90M | 52.30M |
| Interest Income | 0.00 | 1.01M | 1.04M | 549.00K | 440.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.74M | 3.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.01M | 1.01M | 920.00K | 549.00K | 440.00K | 331.00K | 433.00K | 2.14M | 3.71M | 602.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 2.56M | 5.37M | 5.50M | 4.52M | 3.80M | 3.69M | 4.27M | 5.03M | 2.39M | 1.43M | 2.03M | 3.05M | 1.98M | 2.84M | 4.61M | 5.61M | 5.76M | 5.82M | 5.92M | 6.80M | 7.82M | 4.99M | 2.08M | 1.20M | 300.00K | 100.00K |
| EBITDA | 3.84M | -2.27M | -1.33M | -20.10M | -21.72M | -8.57M | -9.01M | -2.16M | -35.47M | -13.35M | -212.00K | 725.00K | -1.67M | -3.08M | -14.16M | -28.97M | -8.67M | 16.42M | -5.39M | 41.89M | 28.08M | -39.59M | 17.70M | 42.95M | 16.90M | 10.00M | 3.00M |
| EBITDA Ratio | 9.54% | -11.88% | -19.80% | -66.75% | -83.41% | -32.34% | -67.75% | -85.25% | -274.86% | -7.55% | -1.89% | 19.90% | -1.04% | -1.71% | -5.33% | -25.78% | -6.50% | 5.62% | -7.99% | 11.07% | 8.73% | -13.34% | 2.21% | 9.14% | 8.35% | 7.42% | 16.45% |
| Operating Income | 2.80M | -3.84M | -11.74M | -26.56M | -23.93M | -12.12M | -6.29M | -6.44M | -40.41M | -13.47M | -4.28M | -25.23M | -4.70M | -4.31M | -40.58M | -36.43M | -14.28M | 5.91M | -26.89M | 35.19M | 19.59M | -50.18M | 12.71M | 40.88M | 15.70M | 9.20M | 2.40M |
| Operating Income Ratio | 6.97% | -12.06% | -28.41% | -81.96% | -99.39% | -55.35% | -39.59% | -49.23% | -428.41% | -11.23% | -2.84% | -19.88% | -2.99% | -2.98% | -47.81% | -32.37% | -12.19% | 2.47% | -8.42% | 9.66% | 6.17% | -17.67% | 1.82% | 9.81% | 8.98% | 9.10% | 4.39% |
| Total Other Income/Expenses | -1.68M | -2.22M | -1.41M | -82.00K | -244.00K | -582.00K | -6.84M | -2.13M | -3.80M | -670.00K | -2.90M | -24.25M | -939.00K | 414.00K | -26.89M | 2.51M | 4.68M | 4.74M | 15.68M | 1.89M | -1.03M | 1.97M | 2.28M | 4.86M | 2.20M | 2.00M | -6.20M |
| Income Before Tax | 1.13M | -5.84M | -15.41M | -26.15M | -26.67M | -12.19M | -13.13M | -8.57M | -44.21M | -14.14M | -4.34M | -25.26M | -4.72M | -4.17M | -40.39M | -33.59M | -8.21M | 10.65M | -19.25M | 35.97M | 20.66M | -48.21M | 14.98M | 45.74M | 17.90M | 11.20M | -4.10M |
| Income Before Tax Ratio | 2.81% | -18.33% | -37.31% | -80.71% | -110.75% | -55.66% | -82.61% | -65.51% | -468.68% | -11.79% | -2.87% | -19.91% | -3.00% | -2.88% | -47.59% | -29.85% | -7.01% | 4.45% | -6.03% | 9.87% | 6.51% | -16.97% | 2.15% | 10.97% | 10.23% | 11.08% | -7.50% |
| Income Tax Expense | 17.00K | 29.00K | -667.00K | 53.00K | -28.00K | 18.00K | -395.00K | -162.00K | -13.14M | -4.74M | 180.00K | 208.00K | -939.00K | 414.00K | -6.83M | 875.00K | 1.77M | -724.00K | 201.00K | 14.84M | 8.41M | -17.45M | 8.63M | 18.71M | 7.50M | 1.70M | 6.60M |
| Net Income | 802.00K | -5.87M | -14.75M | -26.20M | -26.64M | -12.19M | -12.22M | -8.33M | -11.36M | -16.07M | -4.57M | -25.53M | -11.91M | -6.81M | -33.56M | -34.46M | -9.97M | 11.81M | -19.45M | 21.13M | 12.26M | -30.76M | 6.35M | 27.03M | 10.40M | 9.50M | -4.20M |
| Net Income Ratio | 1.99% | -18.42% | -35.69% | -80.87% | -110.63% | -55.67% | -76.84% | -63.68% | -120.40% | -13.40% | -3.03% | -20.12% | -7.57% | -4.71% | -39.54% | -30.62% | -8.52% | 4.94% | -6.09% | 5.80% | 3.86% | -10.83% | 0.91% | 6.48% | 5.95% | 9.40% | -7.68% |
| EPS | 0.19 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.77 | -45.88 | -73.38 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.50 | -13.67 | 14.00 | 8.40 | -21.92 | 4.60 | 20.00 | 8.70 | 9.20 | -4.86 |
| EPS Diluted | 0.18 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.75 | -45.88 | -73.36 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.40 | -13.67 | 13.70 | 8.30 | -21.92 | 4.50 | 19.60 | 8.60 | 9.10 | -4.86 |
| Weighted Avg Shares Out | 4.32M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.57M | 181.60K | 154.75K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.39M | 1.42M | 1.46M | 1.42M | 1.40M | 1.39M | 1.35M | 1.20M | 1.07M | 863.64K |
| Weighted Avg Shares Out (Dil) | 4.36M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.58M | 181.60K | 154.80K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.40M | 1.42M | 1.49M | 1.44M | 1.40M | 1.41M | 1.38M | 1.22M | 1.08M | 863.64K |
Interpace Biosciences Announces Path Forward in Letter to Shareholders
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders:
Interpace Biosciences Announces CFO Leadership Transition
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace's Chief Financial Officer (“CFO”)....
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1,...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
Interpace Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, January 21, 2021
PARSIPPANY, NJ, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that it will hold its third quarter 2020 financial results conference call and webcast after the close of market on Thursday, January 21, 2021 at...
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan
Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Executive Officer by...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due...
Interpace Biosciences (NASDAQ:IDXG) Shares Gap Up to $2.98
Interpace Biosciences, Inc. (NASDAQ:IDXG) shares gapped up prior to trading on Wednesday . The stock had previously closed at $2.98, but opened at $3.56. Interpace Biosciences shares last traded at $4.09, with a volume of 572,556 shares. Several research firms...
Brokerages Anticipate Interpace Diagnostics Group Inc (NASDAQ:IDXG) to Post -$1.64 Earnings Per Share
Wall Street analysts forecast that Interpace Diagnostics Group Inc (NASDAQ:IDXG) will post earnings of ($1.64) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Interpace Diagnostics Group’s earnings. The highest EPS estimate is ($1.56)...
Source: https://incomestatements.info
Category: Stock Reports